# BridgeBio Oncology Therapeutics, Inc.: filings BBOT · Nasdaq · CIK 1869105 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/bbot.md) · [Financials](/companies/bbot/financials.md) · [Filings](/companies/bbot/filings.md) · [Insiders](/companies/bbot/insiders.md) ## Reports and events: 39 filings Newest first, by EDGAR acceptance time (Eastern). Filter with ?form= one of: `periodic`, `8-K`, `10-K`, `10-Q`, `4`, `proxy`, `13dg`, `all`, or any form this company filed (4 48, 3 21, 8-K 19, 424B3 12, CORRESP 9, 10-Q 8, EFFECT 7, UPLOAD 7, 425 6, SC 13G 4, SCHEDULE 13G 4, POS AM 3, SCHEDULE 13D/A 3, SCHEDULE 13G/A 3, 10-K 2, 424B4 2, DRS 2, DRSLTR 2, S-1 2, S-1/A 2, S-4/A 2, S-8 2, 8-A12B 1, ARS 1, CERT 1, DEF 14A 1, DEFA14A 1, DRS/A 1, S-1MEF 1, S-3 1, S-4 1, SC 13D 1, SCHEDULE 13D 1). | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-08 | 20:19 ET | [8-K](/filings/0001193125-26-385225.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-385225 | | 2026-08-11 | 20:12 ET | [10-Q](/filings/0001193125-26-344661.md) | Quarterly report, period 2026-06-30 | 0001193125-26-344661 | | 2026-08-11 | 20:07 ET | [8-K](/filings/0001193125-26-344608.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-344608 | | 2026-07-06 | 20:37 ET | [SCHEDULE 13D/A](/filings/0001213900-26-075546.md) | Ownership report, active investor, amended | 0001213900-26-075546 | | 2026-06-22 | 20:05 ET | [8-K](/filings/0001193125-26-277513.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results | 0001193125-26-277513 | | 2026-05-12 | 21:11 ET | [10-Q](/filings/0001193125-26-219829.md) | Quarterly report, period 2026-03-31 | 0001193125-26-219829 | | 2026-05-12 | 21:07 ET | [8-K](/filings/0001193125-26-219801.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-219801 | | 2026-04-29 | 20:05 ET | [8-K](/filings/0001193125-26-191512.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-191512 | | 2026-04-28 | 20:06 ET | [DEF 14A](/filings/0001193125-26-186944.md) | Proxy statement, period 2026-06-16 | 0001193125-26-186944 | | 2026-04-23 | 21:31 ET | [8-K](/filings/0001193125-26-170888.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-170888 | | 2026-03-26 | 20:52 ET | [8-K](/filings/0001193125-26-126493.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-126493 | | 2026-03-05 | 21:40 ET | [10-K](/filings/0001193125-26-094112.md) | Annual report, period 2025-12-31 | 0001193125-26-094112 | | 2026-03-05 | 21:15 ET | [8-K](/filings/0001193125-26-093997.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-093997 | | 2026-01-07 | 12:09 ET | [8-K](/filings/0001193125-26-005425.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-005425 | | 2025-11-12 | 21:52 ET | [10-Q](/filings/0001193125-25-277834.md) | Quarterly report, period 2025-09-30 | 0001193125-25-277834 | | 2025-11-12 | 21:12 ET | [8-K](/filings/0001193125-25-277601.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-277601 | | 2025-08-29 | 20:08 ET | [S-1](/filings/0001193125-25-192760.md) | Registration statement | 0001193125-25-192760 | | 2025-08-18 | 21:41 ET | [SCHEDULE 13D](/filings/0001193125-25-182790.md) | Ownership report, active investor | 0001193125-25-182790 | | 2025-08-13 | 12:29 ET | [SCHEDULE 13D/A](/filings/0001213900-25-075307.md) | Ownership report, active investor, amended | 0001213900-25-075307 | | 2025-08-13 | 00:54 ET | [8-K](/filings/0001213900-25-075190.md) | 1.01 Entry into a material agreement; 2.01 Completion of an acquisition or disposition; 3.02 Unregistered sale of equity; 3.03 Change to security holders’ rights; 4.01 Change of auditor; 5.01 Change in control; 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 5.05 Item not in the standard list; 5.06 Item not in the standard list; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-25-075190 | | 2025-08-06 | 11:34 ET | [8-K](/filings/0001213900-25-072312.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-25-072312 | | 2025-08-04 | 20:45 ET | [8-K](/filings/0001213900-25-071392.md) | 5.07 Shareholder vote results | 0001213900-25-071392 | | 2025-08-01 | 20:47 ET | [10-Q](/filings/0001213900-25-070659.md) | Quarterly report, period 2025-06-30 | 0001213900-25-070659 | | 2025-07-11 | 11:44 ET | [8-K](/filings/0001213900-25-062955.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-25-062955 | | 2025-05-15 | 21:26 ET | [10-Q](/filings/0001213900-25-044424.md) | Quarterly report, period 2025-03-31 | 0001213900-25-044424 | | 2025-03-11 | 00:31 ET | [10-K](/filings/0001213900-25-022387.md) | Annual report, period 2024-12-31 | 0001213900-25-022387 | | 2025-03-04 | 23:43 ET | [SCHEDULE 13D/A](/filings/0001213900-25-020316.md) | Ownership report, active investor, amended | 0001213900-25-020316 | | 2025-03-03 | 02:56 ET | [8-K](/filings/0001213900-25-018997.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001213900-25-018997 | | 2025-02-28 | 13:03 ET | [8-K](/filings/0001213900-25-018334.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-25-018334 | | 2025-02-10 | 11:05 ET | [8-K](/filings/0001213900-25-011454.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001213900-25-011454 | | 2024-11-14 | 21:30 ET | [10-Q](/filings/0001213900-24-098483.md) | Quarterly report, period 2024-09-30 | 0001213900-24-098483 | | 2024-08-14 | 12:47 ET | [10-Q](/filings/0001213900-24-068630.md) | Quarterly report, period 2024-06-30 | 0001213900-24-068630 | | 2024-05-15 | 20:05 ET | [10-Q](/filings/0001213900-24-043582.md) | Quarterly report, period 2024-03-31 | 0001213900-24-043582 | | 2024-02-20 | 00:48 ET | [SC 13D](/filings/0001213900-24-015480.md) | Ownership report, active investor | 0001213900-24-015480 | | 2024-02-20 | 21:20 ET | [8-K](/filings/0001213900-24-015329.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-24-015329 | | 2024-02-14 | 12:35 ET | [8-K](/filings/0001213900-24-013637.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-24-013637 | | 2024-02-07 | 02:18 ET | [S-1/A](/filings/0001213900-24-010676.md) | Registration statement, amended | 0001213900-24-010676 | | 2024-02-02 | 18:04 ET | [S-1/A](/filings/0001213900-24-009481.md) | Registration statement, amended | 0001213900-24-009481 | | 2024-01-18 | 22:24 ET | [S-1](/filings/0001213900-24-004590.md) | Registration statement | 0001213900-24-004590 | Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:06 ET. No prices; not investment advice.